Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Beyond the biotech IPO: a brave new world

Nature Biotechnology volume 27, pages 705–709 (2009)Cite this article

After a decade of significant challenges, biotech's long-term sustainability depends on making fundamental changes to its traditional business model.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: IPO windows and pricing.
Figure 2: Poor post-market performance.
Figure 3: Illiquid trading volumes.
Figure 4: The binary nature of public product-focused biotech plays.

References

  1. Mack, G. Nat. Biotechnol. 26, 960–961 (2008).

    Article  CAS  Google Scholar 

  2. Licking, E.F. Startup 2–18 (May 2009).

    Google Scholar 

  3. Geilinger, U. & Leo, C. Trade Sales of Biotechnology and Specialty Pharma Companies 2005–2008 (HBM Partners, Zug, Switzerland, 2009) http://www.hbmpartners.com/survey/Survey%202005-2008/HBM%20Pharma%20Biotech%20M&A%20Survey%202005-2008.pdf

    Google Scholar 

Download references

Acknowledgements

The author would like to thank A. Milne at Atlas Venture for her tireless data analysis and insightful support, as well as all the firms who helped contribute data sets.

Author information

Authors and Affiliations

  1. Bruce L. Booth is a partner at Atlas Venture, Waltham, Massachusetts, USA. bbooth@atlasventure.com,

    Bruce L Booth

Authors
  1. Bruce L Booth
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Atlas Venture is an investment firm focused on early-stage biotech. B.L.B. has a pecuniary interest in Atlas's success.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Booth, B. Beyond the biotech IPO: a brave new world. Nat Biotechnol 27, 705–709 (2009). https://doi.org/10.1038/nbt0809-705

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0809-705

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing